Fig. 2

The TMI was used for docetaxel and atezolizumab stratification in the discovery cohort (OAK cohort). Top Kaplan-Meier plots of OS in NSCLC patients receiving docetaxel when the TMI cut-off was set at the median value. For responders, the median OS duration was 11.86 months (n = 159); for non-responders, the median OS duration was 6.31 months (n = 159). The HRs of all patients and the corresponding subgroups are shown on the top right. Bottom Kaplan-Meier plots of OS in NSCLC patients receiving atezolizumab when the TMI cut-off was set at the median value. For responders, the median OS duration was 18.10 months (n = 150); for non-responders, the median OS duration was 7.89 months (n = 174). The HRs of all patients and the corresponding subgroups are shown on the lower right